CUE News - Candlesense

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

Conference

1 day ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage an...

What are the downside risks if the trial encounters safety issues or fails to meet efficacy benchmarks? Are there any partnership or licensing opportunities tied to CUE‑102 that could affect future cash‑flow or valuation? What are the key clinical endpoints being evaluated, and how will they be interpreted by analysts?

Clinical trials

9 days ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

How might the recent business highlights influence institutional sentiment and potential fund inflows or outflows? What potential regulatory or reimbursement risks could affect the company's upcoming product launches? Are there any forward‑looking guidance revisions (e.g., revenue, net loss, cash runway) that could influence analyst forecasts?

Earnings

10 days ago